Estela Rodriguez, Associate Director of Community Outreach-Thoracic Oncology at Sylvester Comprehensive Cancer Center, shared on X:
“Hitting the target in lung cancer not as easy as it looks. We heard about many efforts to improve targeted therapy for EGFR, ROS1, ALK, ROS1 this past week – major improvements but still many drugs miss the mark in terms of resistance, toxicity, CNS activity.
What data in lung cancer targeted therapy are you most excited about?”
You might be interested in:
